A Phase 3 interventional study of BGJ398 and Gemcitabine in Advanced Cholangiocarcinoma and FGFR2 Gene Mutation, sponsored by QED Therapeutics, Inc.. Terminated at 116 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by QED Therapeutics, Inc. (part of BridgeBio) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.
Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 134th largest by enrollment of the 279 interventional ones that give a count, is one of 26 that started in 2019, is one of 18 in phase 3, and was the 144th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
328 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 127 · Phase 2 142 · Phase 3 24 · Phase 4 1
First in 2001; this study’s year is marked. 26 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 44 across the 279 interventional studies, 230 across the 45 observational. Of the 190 that completed or were terminated, 94 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 328 have an industry lead sponsor. The 10 most frequent:
This study is registered under QED Therapeutics, Inc., one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
BridgeBio has 2 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
36 of the studies in Cholangiocarcinoma with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05948475Phase 3TransThera Sciences (Nanjing), Inc.Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | 2026-12 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06723236MacroGenicsA Study of MGC028 in Participants With Advanced Solid Tumors | 2026-11 |
Add all 36 to your calendar (.ics) → With an account.
Among the 328 studies in Cholangiocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received treatment with any systemic anti-cancer therapy for unresectable locally advanced or cholangiocarcinoma, with following exceptions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Drug: BGJ398
Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
Drug: Gemcitabine · Drug: Cisplatin
Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Also known as: Infigratinib
Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Progression-free Survival (Central Imaging Assessment)
Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors \[RECIST\] v. 1.1) or death, whichever occurs first.
Time frame: From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin
OS by investigator assessment, defined as time from date of randomization until death due to any cause
Time frame: From the time of randomization to time of death. Note: OS is an event driven endpoint. Subjects who had not died (no record of death) or were lost to follow-up were censored at the date of last known to be alive.
Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin
Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first.
Time frame: From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment
ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline
Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Best Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator.
BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date.
Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator.
DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover.
Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator.
DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover.
Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Number of Participants With Adverse Events (AEs)
Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period
Time frame: From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
Number of Participants With Serious Adverse Events (SAEs)
Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period
Time frame: From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
Participants with a diagnosis of advanced/metastatic or inoperable cholangiocarcinoma (CCA) with FGFR2 fusion/rearrangement were recruited to this open-label, randomized, controlled global study across Western Europe, North America, and Asia, based on documented evidence of FGFR2 genetic alteration. The first participant was treated on 18 March 2020. The data cutoff for the analysis was 02 March 2023.
| Milestone | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Started | 29 | 19 |
| Completed | 29 | 17 |
| Not completed | 0 | 2 |
Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors \[RECIST\] v. 1.1) or death, whichever occurs first.
| Months | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Progression-free Survival (Central Imaging Assessment) | 7.39 (0.03 to 12.85) | 8.02 (0.03 to 12.88) |
OS by investigator assessment, defined as time from date of randomization until death due to any cause
| Months | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin | NA (14.36 to NA) | NA (8.02 to NA) |
Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first.
| Months | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin | 7.39 (0.03 to 20.24) | 5.19 (0.03 to 12.88) |
ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline
| Participants | ORR By Central Assessment | ORR By Investigator Assessment | ORR by Central Assessment | ORR by Investigator Assessment |
|---|---|---|---|---|
| Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment | 11 | 9 | 3 | 2 |
BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date.
| Participants | BOR By Central Assessment | BOR By Investigator Assessment | BOR by Central Assessment | BOR by Investigator Assessment |
|---|---|---|---|---|
| Confirmed complete response | 0 | 0 | 0 | 0 |
| Confirmed partial response | 11 | 9 | 3 | 2 |
| Stable disease | 14 | 19 | 11 | 12 |
| Progressive disease | 2 | 0 | 2 | 3 |
| Not done | 2 | 1 | 3 | 2 |
DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover.
| Months | DOR By Central Assessment | DOR By Investigator Assessment | DOR by Central Assessment | DOR by Investigator Assessment |
|---|---|---|---|---|
| Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator. | 5.59 (3.71 to NA) | 7.52 (3.71 to NA) | NA (3.94 to NA) | NA (8.08 to NA) |
DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover.
| Participants | DCR By Central Assessment | DCR By Investigator Assessment | DCR by Central Assessment | DCR by Investigator Assessment |
|---|---|---|---|---|
| Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator. | 25 | 28 | 14 | 14 |
Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period
| Participants | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 29 | 17 |
Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period
| Participants | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 10 | 0 |
Collected over From the the time of the first administration of study treatment through 30 days after their last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infigratinib (BGJ398) 125 mg | 0/29 (0%) | 10/29 (34.5%) | 29/29 (100%) |
| Gemcitabine + Cisplatin | 0/17 (0%) | 0/17 (0%) | 17/17 (100%) |
| Event | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| StomatitisGastrointestinal disorders | 2/29 | 0/17 |
| COVID-19Infections and infestations | 2/29 | 0/17 |
| Eye painEye disorders | 1/29 | 0/17 |
| DysphagiaGastrointestinal disorders | 1/29 | 0/17 |
| FatigueGeneral disorders | 1/29 | 0/17 |
| SepsisInfections and infestations | 1/29 | 0/17 |
| CalciphylaxisMetabolism and nutrition disorders | 1/29 | 0/17 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/29 | 0/17 |
| HyperphosphataemiaMetabolism and nutrition disorders | 1/29 | 0/17 |
| HypokalaemiaMetabolism and nutrition disorders | 1/29 | 0/17 |
| Event | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin |
|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 26/29 | 0/17 |
| NauseaGastrointestinal disorders | 7/29 | 11/17 |
| ConstipationGastrointestinal disorders | 14/29 | 4/17 |
| FatigueGeneral disorders | 12/29 | 8/17 |
| DiarrhoeaGastrointestinal disorders | 13/29 | 5/17 |
| Decreased appetiteMetabolism and nutrition disorders | 12/29 | 5/17 |
| HypophosphataemiaMetabolism and nutrition disorders | 12/29 | 1/17 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/29 | 1/17 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 12/29 | 0/17 |
| AnaemiaBlood and lymphatic system disorders | 5/29 | 7/17 |
| Age, Categorical(Participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 13 | 34 |
| >=65 years | 8 | 6 | 14 |
| Age, Continuous(years) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 54 ± 13.22 | 58.2 ± 15.25 | 55.8 ± 14.04 |
| Sex: Female, Male(Participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Female | 19 | 10 | 29 |
| Male | 10 | 9 | 19 |
| Race (NIH/OMB)(Participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 3 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 20 | 14 | 34 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| North America | 12 | 7 | 19 |
| Europe | 14 | 8 | 22 |
| Southeast Asia | 3 | 4 | 7 |
| BMI(kg/m2) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 28.41 ± 7.018 | 26.83 ± 8.019 | 27.79 ± 7.388 |
| ECOG PS(Participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| 0 | 19 | 8 | 27 |
| 1 | 10 | 11 | 21 |
| 2 | 0 | 0 | 0 |
| Primary site of cholangiocarcinoma(Participants) | Infigratinib (BGJ398) 125 mg | Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Common bile duct | 1 | 1 | 2 |
| Intrahepatic bile duct | 28 | 17 | 45 |
| Other | 0 | 1 | 1 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 116 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Mar 2023, 38 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib